Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

تأخير الانتشار المحلي - 2/4/2020


                  
تأخير الانتشار المحلي 2/4/2020                                                                                  العدد الإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020


         
 العدد الإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020                          العدد اليومي والإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020
 


The scale of 5000 is based on a realistic estimation of the capacity of the health care system.

If 5000 people are infected, about 20% would need hospital care (1000 patient), 5% would be admitted in intensive care units (250 patients), while 2-3% would need mechanical ventilation (150 patients).

Knowing that 5000 is a cumulative number starting Feb. 21as shown in figure 3. It is worth mentioning, that the 1000 patients are not expected to be all hospitalized at the same time. They will rather be progressively admitted and discharged over the considered period of time. Calculation done in terms of patient days shows that the demand generated by 5000 positive cases would remain compatible with the health system capacity.

The hospital capacity is expected to be 576 beds + 234 ICU beds + 263 ventilators, all dedicated to covid-19 patients, by April 1st 2020. Knowing that this capacity will gradually be enhanced (raising the bar of the figure 1).

Our strategy is to flatten the curve while increasing the capacity of the health care system to adequately respond to this pandemic.

Help us by following the instructions of the Ministry of Public Health and most of all STAY AT HOME.







































The scale of 5000 is based on a realistic estimation of the capacity of the health care system.
If 5000 people are infected, about 20% would need hospital care (1000 patient), 5% would be admitted in intensive care units (250 patients), while 2-3% would need mechanical ventilation (150 patients).
Knowing that 5000 is a cumulative number starting Feb. 21as shown in figure 3. It is worth mentioning, that the 1000 patients are not expected to be all hospitalized at the same time. They will rather be progressively admitted and discharged over the considered period of time. Calculation done in terms of patient days shows that the demand generated by 5000 positive cases would remain compatible with the health system capacity.
The hospital capacity is expected to be 576 beds + 234 ICU beds + 263 ventilators, all dedicated to covid-19 patients, by April 1st 2020. Knowing that this capacity will gradually be enhanced (raising the bar of the figure 1).

Our strategy is to flatten the curve while increasing the capacity of the health care system to adequately respond to this pandemic.

Help us by following the instructions of the Ministry of Public Health and most of all STAY AT HOME.
    ...
    94
    ...
ATC Name B/G Ingredients Dosage Form Price
J01XA01 ZERMACIN G Vancomycin (HCl) - 0.5g 0.5g Injectable sterile lyophilised powder for solution 5,875,791 L.L
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension L.L
R07AA INFASURF B Calfactant - 210mg/6ml 35mg/ml Injectable suspension 40,596,749 L.L
R07AA INFASURF B Calfactant - 105mg/3ml 35mg/ml Injectable suspension 23,344,161 L.L
L01BC07 AZACITIDINE ARROW G Azacitidine - 25mg/ml 25mg/ml Injectable suspension 10,967,854 L.L
L01BC07 LEUZADA G Azacitidine - 100mg 100mg Injectable suspension 10,969,285 L.L
L02AE03 ZOLADEX DEPOT B Goserelin (acetate) - 3.6mg 3.6mg Injectable suspension 8,820,074 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension 35,121,328 L.L
A10AB04 HUMALOG BioTech Insulin lispro - 100IU/ml 100IU/ml Injectable suspension 1,988,887 L.L
N02CD02 EMGALITY BioTech Galcanezumab - 120mg/ml 120mg/ml Injectable suspension 37,250,732 L.L
A10AB04 PROLOG BioTech Insulin lispro - 100U/ml 100U/ml Injectable suspension 1,503,312 L.L
A10AD01 HUMULIN 70/30 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 701,486 L.L
A10AD01 JUSLINE BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 401,809 L.L
A10AD01 MIXTARD 30 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A10AD01 MIXTARD 30 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A10AD04 HUMALOG MIX 50 KWIKPEN BioTech Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50% 100IU/ml Injectable suspension 3,950,897 L.L
A10AD04 HUMALOG MIX 25 KWIKPEN BioTech Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75% 100IU/ml Injectable suspension 3,950,897 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
A10AE01 HUMULIN N U-100 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 701,486 L.L
A10AE01 INSULATARD BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A10AE01 INSULATARD BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A10AE01 JUSLINE N BioTech Insulin human isophane - 100IU/ml 100IU/ml Injectable suspension 401,809 L.L
J07AJ51 BOOSTRIX B Diphteria toxoid purified - ?2.5Lf/0.5ml, Tetanus toxoid purified - ?5Lf/0.5ml, Bordetella Pertussis Antigens: toxoid - 8mcg/0.5ml, Bordetella Pertussis Antigens: filamentous haemagglutinin - 8mcg/0.5ml, Pertactine - 2.5mcg Al3+/0.5ml, Aluminium hydroxide - 0.3mg Al3+/0.5ml, Aluminium Phosphate - 0.2mg/0.5ml Injectable suspension 1,394,909 L.L
J07AL02 PREVENAR 13 B Polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 23F (2.2mcg)Polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 6,352,343 L.L
J07AL02 SYNFLORIX B Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg Injectable suspension 4,675,228 L.L
J07AL02 PNEUMOSIL (10-VALENT) G Pneumococcal polysaccharide conjugate vaccine (adsorbed) - Injectable suspension 3,386,483 L.L
    ...
    94
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026